The estimated Net Worth of Rajesh C Md Shrotriya is at least 30.5 百万$ dollars as of 17 May 2018. Rajesh Shrotriya owns over 362,926 units of CASI Pharmaceuticals Inc stock worth over 4,255,014$ and over the last 21 years he sold CASI stock worth over 26,073,379$. In addition, he makes 125,600$ as Independent Director at CASI Pharmaceuticals Inc.
Rajesh has made over 27 trades of the CASI Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 362,926 units of CASI stock worth 529,872$ on 17 May 2018.
The largest trade he's ever made was exercising 5,199,584 units of CASI Pharmaceuticals Inc stock on 9 January 2018 worth over 39,516,838$. On average, Rajesh trades about 88,166 units every 23 days since 2003. As of 17 May 2018 he still owns at least 563,578 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Rajesh Shrotriya stock trades at the bottom of the page.
Dr. Rajesh C. Shrotriya M.D. serves as Independent Director of the Company. Dr. Shrotriya has been a director of the Company since September 2014. From 2000 – 2017, he was President and Chief Operating Officer and Chief Executive Officer of Spectrum Pharmaceuticals. In this capacity, he spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. He is also a Director of the UNVL Foundation. Prior to joining Spectrum, from September 2000 to August 2002, Dr. Shrotriya was President and COO of Neotherapeutics, Inc., and prior to that he was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.
As the Independent Director of CASI Pharmaceuticals Inc, the total compensation of Rajesh Shrotriya at CASI Pharmaceuticals Inc is 125,600$. There are 10 executives at CASI Pharmaceuticals Inc getting paid more, with Wei-Wu He having the highest compensation of 9,269,690$.
Rajesh Shrotriya is 76, he's been the Independent Director of CASI Pharmaceuticals Inc since 2019. There are no older and 11 younger executives at CASI Pharmaceuticals Inc.
Rajesh's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DR. SUITE 300, ROCKVILLE, MD, 20850.
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over 0$ worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth 51,898,666$ . The most active insiders traders include Wei Wu He、Rajesh C Md Shrotriya、Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of 6,141,555$. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth 229,516$.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: